PL186615B1 - Zastosowanie epinastyny - Google Patents

Zastosowanie epinastyny

Info

Publication number: PL186615B1
Authority: PL; Poland
Prior art keywords: epinastine; migraine; pain; treatment; medicament
Prior art date: 1995-11-14

Application number

PL96326653A

Other languages

English (en)

Polish (pl)

Other versions

PL326653A1 (en

Inventor

Birgit Jung

Christopher J. M. Meade

Michel Pairet

Original Assignee

Boehringer Ingelheim Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-14

Filing date

1996-11-13

Publication date

2004-02-27

1996-11-13 Application filed by Boehringer Ingelheim Kg filed Critical Boehringer Ingelheim Kg

1998-10-12 Publication of PL326653A1 publication Critical patent/PL326653A1/xx

2004-02-27 Publication of PL186615B1 publication Critical patent/PL186615B1/pl

Links

238000011282 treatment Methods 0.000 title claims abstract description 25
208000002193 Pain Diseases 0.000 title claims abstract description 18
230000036407 pain Effects 0.000 title claims abstract description 17
229960003449 epinastine Drugs 0.000 claims abstract description 68
WHWZLSFABNNENI-UHFFFAOYSA-N epinastine Chemical compound C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 WHWZLSFABNNENI-UHFFFAOYSA-N 0.000 claims abstract description 68
208000019695 Migraine disease Diseases 0.000 claims abstract description 22
239000003814 drug Substances 0.000 claims abstract description 21
206010043269 Tension headache Diseases 0.000 claims abstract description 10
208000008548 Tension-Type Headache Diseases 0.000 claims abstract description 10
230000004054 inflammatory process Effects 0.000 claims abstract description 10
208000006561 Cluster Headache Diseases 0.000 claims abstract description 8
208000000112 Myalgia Diseases 0.000 claims abstract description 8
208000018912 cluster headache syndrome Diseases 0.000 claims abstract description 8
208000004296 neuralgia Diseases 0.000 claims abstract description 8
229940079593 drug Drugs 0.000 claims abstract description 7
206010061218 Inflammation Diseases 0.000 claims abstract description 4
206010027599 migraine Diseases 0.000 claims description 21
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 16
238000004519 manufacturing process Methods 0.000 claims description 12
HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims description 10
239000004480 active ingredient Substances 0.000 claims description 10
230000000202 analgesic effect Effects 0.000 claims description 10
229960001680 ibuprofen Drugs 0.000 claims description 10
238000000034 method Methods 0.000 claims description 10
239000000203 mixture Substances 0.000 claims description 10
230000000694 effects Effects 0.000 claims description 9
239000000126 substance Substances 0.000 claims description 9
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical group C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 8
229940127291 Calcium channel antagonist Drugs 0.000 claims description 6
201000002481 Myositis Diseases 0.000 claims description 6
239000002876 beta blocker Substances 0.000 claims description 6
229940097320 beta blocking agent Drugs 0.000 claims description 6
239000000480 calcium channel blocker Substances 0.000 claims description 6
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims description 6
208000013465 muscle pain Diseases 0.000 claims description 6
229940123603 Dopamine D2 receptor antagonist Drugs 0.000 claims description 5
239000002253 acid Substances 0.000 claims description 5
229960003133 ergot alkaloid Drugs 0.000 claims description 5
150000003839 salts Chemical class 0.000 claims description 5
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 4
230000006378 damage Effects 0.000 claims description 4
239000000442 dopamine 2 receptor blocking agent Substances 0.000 claims description 4
VKXSGUIOOQPGAF-UHFFFAOYSA-N epinastine hydrochloride Chemical compound [H+].[Cl-].C1C2=CC=CC=C2C2CN=C(N)N2C2=CC=CC=C21 VKXSGUIOOQPGAF-UHFFFAOYSA-N 0.000 claims description 4
SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical group C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 claims description 4
229960000326 flunarizine Drugs 0.000 claims description 4
239000012458 free base Substances 0.000 claims description 4
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 4
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 4
229960005489 paracetamol Drugs 0.000 claims description 4
229960004572 pizotifen Drugs 0.000 claims description 4
FIADGNVRKBPQEU-UHFFFAOYSA-N pizotifen Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1C=CS2 FIADGNVRKBPQEU-UHFFFAOYSA-N 0.000 claims description 4
229960003712 propranolol Drugs 0.000 claims description 4
229960003708 sumatriptan Drugs 0.000 claims description 4
KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical group CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 claims description 4
KPJZHOPZRAFDTN-ZRGWGRIASA-N (6aR,9R)-N-[(2S)-1-hydroxybutan-2-yl]-4,7-dimethyl-6,6a,8,9-tetrahydroindolo[4,3-fg]quinoline-9-carboxamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@H](CO)CC)C2)=C3C2=CN(C)C3=C1 KPJZHOPZRAFDTN-ZRGWGRIASA-N 0.000 claims description 3
JQSAYKKFZOSZGJ-UHFFFAOYSA-N 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine Chemical compound COC1=C(OC)C(OC)=CC=C1CN1CCN(C(C=2C=CC(F)=CC=2)C=2C=CC(F)=CC=2)CC1 JQSAYKKFZOSZGJ-UHFFFAOYSA-N 0.000 claims description 3
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 claims description 3
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 claims description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 3
CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims description 3
239000000556 agonist Substances 0.000 claims description 3
229960002896 clonidine Drugs 0.000 claims description 3
229950005624 dotarizine Drugs 0.000 claims description 3
LRMJAFKKJLRDLE-UHFFFAOYSA-N dotarizine Chemical compound O1CCOC1(C=1C=CC=CC=1)CCCN(CC1)CCN1C(C=1C=CC=CC=1)C1=CC=CC=C1 LRMJAFKKJLRDLE-UHFFFAOYSA-N 0.000 claims description 3
229960004943 ergotamine Drugs 0.000 claims description 3
OFKDAAIKGIBASY-VFGNJEKYSA-N ergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C3=CC=CC4=NC=C([C]34)C2)=C1)C)C1=CC=CC=C1 OFKDAAIKGIBASY-VFGNJEKYSA-N 0.000 claims description 3
XCGSFFUVFURLIX-UHFFFAOYSA-N ergotaminine Natural products C1=C(C=2C=CC=C3NC=C(C=23)C2)C2N(C)CC1C(=O)NC(C(N12)=O)(C)OC1(O)C1CCCN1C(=O)C2CC1=CC=CC=C1 XCGSFFUVFURLIX-UHFFFAOYSA-N 0.000 claims description 3
229960000905 indomethacin Drugs 0.000 claims description 3
229950007692 lomerizine Drugs 0.000 claims description 3
229960001929 meloxicam Drugs 0.000 claims description 3
229960001186 methysergide Drugs 0.000 claims description 3
TTWJBBZEZQICBI-UHFFFAOYSA-N metoclopramide Chemical group CCN(CC)CCNC(=O)C1=CC(Cl)=C(N)C=C1OC TTWJBBZEZQICBI-UHFFFAOYSA-N 0.000 claims description 3
229960004503 metoclopramide Drugs 0.000 claims description 3
229960002237 metoprolol Drugs 0.000 claims description 3
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 3
229960002009 naproxen Drugs 0.000 claims description 3
CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims description 3
229960005254 naratriptan Drugs 0.000 claims description 3
UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 claims description 3
ULFRLSNUDGIQQP-UHFFFAOYSA-N rizatriptan Chemical compound C1=C2C(CCN(C)C)=CNC2=CC=C1CN1C=NC=N1 ULFRLSNUDGIQQP-UHFFFAOYSA-N 0.000 claims description 3
208000024891 symptom Diseases 0.000 claims description 3
206010065390 Inflammatory pain Diseases 0.000 claims description 2
229960004704 dihydroergotamine Drugs 0.000 claims description 2
HESHRHUZIWVEAJ-JGRZULCMSA-N dihydroergotamine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C)C1=CC=CC=C1 HESHRHUZIWVEAJ-JGRZULCMSA-N 0.000 claims description 2
210000003734 kidney Anatomy 0.000 claims description 2
210000004185 liver Anatomy 0.000 claims description 2
229960004650 metergoline Drugs 0.000 claims description 2
WZHJKEUHNJHDLS-QTGUNEKASA-N metergoline Chemical compound C([C@H]1CN([C@H]2[C@@H](C=3C=CC=C4N(C)C=C(C=34)C2)C1)C)NC(=O)OCC1=CC=CC=C1 WZHJKEUHNJHDLS-QTGUNEKASA-N 0.000 claims description 2
230000000144 pharmacologic effect Effects 0.000 claims description 2
239000002462 tachykinin receptor antagonist Substances 0.000 claims description 2
238000002560 therapeutic procedure Methods 0.000 claims description 2
206010019233 Headaches Diseases 0.000 claims 8
231100000869 headache Toxicity 0.000 claims 8
230000001684 chronic effect Effects 0.000 claims 5
201000010099 disease Diseases 0.000 claims 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
208000002173 dizziness Diseases 0.000 claims 2
238000011321 prophylaxis Methods 0.000 claims 2
230000000306 recurrent effect Effects 0.000 claims 2
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 1
206010052613 Allergic bronchitis Diseases 0.000 claims 1
208000025978 Athletic injury Diseases 0.000 claims 1
208000000094 Chronic Pain Diseases 0.000 claims 1
206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims 1
206010039085 Rhinitis allergic Diseases 0.000 claims 1
206010042496 Sunburn Diseases 0.000 claims 1
208000002205 allergic conjunctivitis Diseases 0.000 claims 1
208000026935 allergic disease Diseases 0.000 claims 1
201000010105 allergic rhinitis Diseases 0.000 claims 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 claims 1
206010003246 arthritis Diseases 0.000 claims 1
208000006673 asthma Diseases 0.000 claims 1
208000024998 atopic conjunctivitis Diseases 0.000 claims 1
208000013433 lightheadedness Diseases 0.000 claims 1
229960003587 lisuride Drugs 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
238000001228 spectrum Methods 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 claims 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
241000700159 Rattus Species 0.000 description 8
230000027455 binding Effects 0.000 description 8
238000009739 binding Methods 0.000 description 8
COXVTLYNGOIATD-HVMBLDELSA-N CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O Chemical compound CC1=C(C=CC(=C1)C1=CC(C)=C(C=C1)\N=N\C1=C(O)C2=C(N)C(=CC(=C2C=C1)S(O)(=O)=O)S(O)(=O)=O)\N=N\C1=CC=C2C(=CC(=C(N)C2=C1O)S(O)(=O)=O)S(O)(=O)=O COXVTLYNGOIATD-HVMBLDELSA-N 0.000 description 7
229960003699 evans blue Drugs 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
210000001519 tissue Anatomy 0.000 description 6
108091005436 5-HT7 receptors Proteins 0.000 description 5
206010015866 Extravasation Diseases 0.000 description 5
208000000114 Pain Threshold Diseases 0.000 description 5
238000010171 animal model Methods 0.000 description 5
230000036251 extravasation Effects 0.000 description 5
230000037040 pain threshold Effects 0.000 description 5
108020003175 receptors Proteins 0.000 description 5
102000005962 receptors Human genes 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
239000000443 aerosol Substances 0.000 description 4
239000000739 antihistaminic agent Substances 0.000 description 4
210000002683 foot Anatomy 0.000 description 4
230000007794 irritation Effects 0.000 description 4
239000002674 ointment Substances 0.000 description 4
210000000427 trigeminal ganglion Anatomy 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
229940125715 antihistaminic agent Drugs 0.000 description 3
230000000052 comparative effect Effects 0.000 description 3
210000001951 dura mater Anatomy 0.000 description 3
-1 ergot alkaloid Substances 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
239000003446 ligand Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
WKZLNEWVIAGNAW-UHFFFAOYSA-N 5-Carboxyamidotryptamine Chemical compound C1=C(C(N)=O)C=C2C(CCN)=CNC2=C1 WKZLNEWVIAGNAW-UHFFFAOYSA-N 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
208000004454 Hyperalgesia Diseases 0.000 description 2
208000035154 Hyperesthesia Diseases 0.000 description 2
ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 2
239000005557 antagonist Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000006073 displacement reaction Methods 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
230000003993 interaction Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229960004958 ketotifen Drugs 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 2
229960000582 mepyramine Drugs 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
239000002245 particle Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
239000000725 suspension Substances 0.000 description 2
QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 1
PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
102100024304 Protachykinin-1 Human genes 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
101800003906 Substance P Proteins 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
230000001387 anti-histamine Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000001926 citrus aurantium l. subsp. bergamia wright et arn. oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
238000011157 data evaluation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
229910000071 diazene Inorganic materials 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
RMGVZKRVHHSUIM-UHFFFAOYSA-L dithionate(2-) Chemical compound [O-]S(=O)(=O)S([O-])(=O)=O RMGVZKRVHHSUIM-UHFFFAOYSA-L 0.000 description 1
238000013213 extrapolation Methods 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
210000001037 metacarpus Anatomy 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
229940105631 nembutal Drugs 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
230000008058 pain sensation Effects 0.000 description 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
230000001936 parietal effect Effects 0.000 description 1
WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
239000000952 serotonin receptor agonist Substances 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008347 soybean phospholipid Substances 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Plant Substances (AREA)

PL96326653A 1995-11-14 1996-11-13 Zastosowanie epinastyny PL186615B1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19542281A DE19542281C2 (de)	1995-11-14	1995-11-14	Verwendung von Epinastin für die Behandlung der Migräne
PCT/EP1996/004957 WO1997017971A1 (de)	1995-11-14	1996-11-13	Verwendung von epinastin für die behandlung von schmerzen

Publications (2)

Publication Number	Publication Date
PL326653A1 PL326653A1 (en)	1998-10-12
PL186615B1 true PL186615B1 (pl)	2004-02-27

Family

ID=7777343

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL96326653A PL186615B1 (pl)	1995-11-14	1996-11-13	Zastosowanie epinastyny

Country Status (32)

Country	Link
US (1)	US5942503A (es)
EP (1)	EP0861081B1 (es)
JP (2)	JP4264850B2 (es)
KR (1)	KR100435611B1 (es)
CN (1)	CN1104242C (es)
AR (1)	AR004321A1 (es)
AT (1)	ATE213160T1 (es)
AU (1)	AU706112B2 (es)
BG (1)	BG62511B1 (es)
BR (1)	BR9611502A (es)
CA (1)	CA2232008C (es)
CO (1)	CO4770978A1 (es)
CZ (1)	CZ290115B6 (es)
DE (2)	DE19542281C2 (es)
DK (1)	DK0861081T3 (es)
EE (1)	EE03512B1 (es)
ES (1)	ES2171746T3 (es)
HK (1)	HK1015280A1 (es)
HU (1)	HU225759B1 (es)
IL (1)	IL123601A (es)
NO (1)	NO982172L (es)
NZ (1)	NZ322467A (es)
PL (1)	PL186615B1 (es)
PT (1)	PT861081E (es)
RO (1)	RO118373B1 (es)
RU (2)	RU2238733C2 (es)
SK (1)	SK61398A3 (es)
TR (1)	TR199800853T2 (es)
TW (1)	TW575423B (es)
UY (1)	UY24354A1 (es)
WO (1)	WO1997017971A1 (es)
ZA (1)	ZA969520B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6586458B1 (en)	1996-08-16	2003-07-01	Pozen Inc.	Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US8022095B2 (en)	1996-08-16	2011-09-20	Pozen, Inc.	Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
RS49982B (sr) *	1997-09-17	2008-09-29	Euro-Celtique S.A.,	Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
ES2234324T3 (es) *	1998-11-02	2005-06-16	MERCK & CO., INC.	Combinaciones de un agonista 5ht1b/1d y un inhibidor selectivo de cox-2 para el tratamiento de la migraña.
WO2000048583A2 (en) *	1999-02-19	2000-08-24	Pozen Inc.	Formulation of 5-ht agonists with nsaids, especially cox-2 inhibitors, for treating migraine
DE19954516A1 (de) *	1999-11-12	2001-05-17	Boehringer Ingelheim Int	Epinastin-haltige Lösungen
DE19958460A1 (de) *	1999-12-03	2001-06-07	Boehringer Ingelheim Pharma	Verfahren zur Herstellung von Epinastine-Hydrochlorid in der hochschmelzenden Kristallmodifikation
JP2002087963A (ja) *	2000-09-08	2002-03-27	Nippon Boehringer Ingelheim Co Ltd	直接打錠により製造されたエピナスチン含有錠剤
US20030104017A1 (en) *	2001-10-26	2003-06-05	Boehringer Ingelheim International Gmbh	Epinastine formulation for oral administration
DE10152973A1 (de) *	2001-10-26	2003-05-08	Boehringer Ingelheim Int	Neue trockene und wässrige Epinastin-Sirup-Formulierung
AU2003250073A1 (en) *	2002-08-02	2004-02-25	Boehringer Ingelheim International Gmbh	Pharmaceutical formulations comprising combinations of epinastine, pseudoephedrine and methylephedrine
MXPA05006954A (es)	2002-12-26	2005-09-22	Pozen Inc	Formas de dosificacion de capas multiples que contienen nsaids y triptanos.
EP1452177A1 (en) *	2003-02-27	2004-09-01	Boehringer Ingelheim International GmbH	Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent
KR20080034916A (ko) *	2005-07-08	2008-04-22	센주 세이야꾸 가부시키가이샤	에피나스틴을 포함하는 경피 흡수 안과 제제
US7247623B2 (en) *	2005-08-19	2007-07-24	Inspire Pharmaceuticals, Inc.	Method of treating dry eye disease with non-drying antihistamines
WO2007110380A1 (en) *	2006-03-25	2007-10-04	Boehringer Ingelheim International Gmbh	Insect bite relief preparation comprising epinastine
US8536445B2 (en) *	2006-06-02	2013-09-17	Emcore Solar Power, Inc.	Inverted metamorphic multijunction solar cells
EP1875899A1 (en) *	2006-06-29	2008-01-09	Laboratorios Del Dr. Esteve, S.A.	Use of 5HT7 receptor agonists for the treatment of pain
US20080102097A1 (en) *	2006-10-31	2008-05-01	Zanella John M	Device and method for treating osteolysis using a drug depot to deliver an anti-inflammatory agent
US8470360B2 (en)	2008-04-18	2013-06-25	Warsaw Orthopedic, Inc.	Drug depots having different release profiles for reducing, preventing or treating pain and inflammation
RU2464984C2 (ru) *	2007-11-22	2012-10-27	Общество с ограниченной ответственностью "МС-Вита"	Нестероидное противовоспалительное лекарственное средство
US8889173B2 (en) *	2008-04-18	2014-11-18	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US9132085B2 (en) *	2008-04-18	2015-09-15	Warsaw Orthopedic, Inc.	Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US8956641B2 (en) *	2008-04-18	2015-02-17	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US8883768B2 (en) *	2008-04-18	2014-11-11	Warsaw Orthopedic, Inc.	Fluocinolone implants to protect against undesirable bone and cartilage destruction
US20090263451A1 (en) *	2008-04-18	2009-10-22	Warsaw Orthopedic, Inc.	Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US9610243B2 (en)	2008-04-18	2017-04-04	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable polymer
US9072727B2 (en) *	2008-04-18	2015-07-07	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US8629172B2 (en)	2008-04-18	2014-01-14	Warsaw Orthopedic, Inc.	Methods and compositions for treating post-operative pain comprising clonidine
US8420114B2 (en) *	2008-04-18	2013-04-16	Warsaw Orthopedic, Inc.	Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US8946277B2 (en)	2008-04-18	2015-02-03	Warsaw Orthopedic, Inc.	Clonidine formulations in a biodegradable polymer carrier
USRE48948E1 (en)	2008-04-18	2022-03-01	Warsaw Orthopedic, Inc.	Clonidine compounds in a biodegradable polymer
US8557273B2 (en)	2008-04-18	2013-10-15	Medtronic, Inc.	Medical devices and methods including polymers having biologically active agents therein
US8722079B2 (en) *	2008-04-18	2014-05-13	Warsaw Orthopedic, Inc.	Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US20090264489A1 (en) *	2008-04-18	2009-10-22	Warsaw Orthopedic, Inc.	Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US20090264477A1 (en) *	2008-04-18	2009-10-22	Warsaw Orthopedic, Inc., An Indiana Corporation	Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263489A1 (en) *	2008-04-18	2009-10-22	Warsaw Orthopedic, Inc.	Analgesic and anti-inflammatory compositions and methods for reducing, preventing or treating pain and inflammation
US9132119B2 (en)	2008-04-18	2015-09-15	Medtronic, Inc.	Clonidine formulation in a polyorthoester carrier
US20100098746A1 (en) *	2008-10-20	2010-04-22	Warsaw Orthopedic, Inc.	Compositions and methods for treating periodontal disease comprising clonidine, sulindac and/or fluocinolone
US8822546B2 (en) *	2008-12-01	2014-09-02	Medtronic, Inc.	Flowable pharmaceutical depot
US20100228097A1 (en) *	2009-03-04	2010-09-09	Warsaw Orthopedic, Inc.	Methods and compositions to diagnose pain
US20100239632A1 (en) *	2009-03-23	2010-09-23	Warsaw Orthopedic, Inc.	Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) *	2009-07-17	2013-12-31	Warsaw Orthopedic, Inc.	Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) *	2009-07-31	2012-07-31	Warsaw Orthopedic, Inc.	Implantable drug depot for weight control
US20110097375A1 (en)	2009-10-26	2011-04-28	Warsaw Orthopedic, Inc.	Formulation for preventing or reducing bleeding at a surgical site
US9988445B2 (en)	2013-09-02	2018-06-05	The University Of Melbourne	Method of treatment of pain by administration of a CCL17 specific antibody
CN105708840A (zh) *	2014-12-01	2016-06-29	重庆安格龙翔医药科技有限公司	一种盐酸依匹斯汀组合物
GB2571696B (en)	2017-10-09	2020-05-27	Compass Pathways Ltd	Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
KR102041389B1 (ko) *	2017-12-12	2019-11-27	(주)프론트바이오	N-(9,13b-디하이드로-1H-디벤조[c,f]이미다조[1,5-a]아제핀-3-일)-2-하이드록시벤즈아미드 및 2-((9,13b-디하이드로-1H-디벤조[c,f]이미다조[1,5-a]아제핀-3-일) 카바모일)페닐 아세테이트의 화합물, 이의 제조방법 및 이를 포함하는 항염증 및 진통제 조성물
CA3138094A1 (en)	2019-04-17	2020-10-22	Compass Pathfinder Limited	Methods for treating anxiety disorders, headache disorders, and eating disorders with psilocybin
JP6963651B2 (ja) *	2020-04-16	2021-11-10	参天製薬株式会社	エピナスチン又はその塩を含有する水性組成物
JP7118579B1 (ja)	2020-04-16	2022-08-16	参天製薬株式会社	エピナスチン又はその塩を含有する水性組成物
CN115448927A (zh) *	2022-10-20	2022-12-09	重庆瑞泊莱医药科技有限公司	一种氢溴酸依匹斯汀晶型ii及其制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3008944A1 (de) *	1980-03-08	1981-09-24	C.H. Boehringer Sohn, 6507 Ingelheim	Dibenzimidazoazepine, ihre herstellung und verwendung

1995
- 1995-11-14 DE DE19542281A patent/DE19542281C2/de not_active Expired - Fee Related
1996
- 1996-10-15 TW TW85112588A patent/TW575423B/zh not_active IP Right Cessation
- 1996-10-24 UY UY24354A patent/UY24354A1/es not_active IP Right Cessation
- 1996-11-13 DE DE59608738T patent/DE59608738D1/de not_active Expired - Lifetime
- 1996-11-13 AT AT96939018T patent/ATE213160T1/de active
- 1996-11-13 US US09/066,392 patent/US5942503A/en not_active Expired - Lifetime
- 1996-11-13 CZ CZ19981498A patent/CZ290115B6/cs not_active IP Right Cessation
- 1996-11-13 HU HU9903489A patent/HU225759B1/hu not_active IP Right Cessation
- 1996-11-13 RU RU2003101430A patent/RU2238733C2/ru not_active IP Right Cessation
- 1996-11-13 ZA ZA969520A patent/ZA969520B/xx unknown
- 1996-11-13 IL IL12360196A patent/IL123601A/en not_active IP Right Cessation
- 1996-11-13 BR BR9611502A patent/BR9611502A/pt not_active IP Right Cessation
- 1996-11-13 SK SK613-98A patent/SK61398A3/sk unknown
- 1996-11-13 ES ES96939018T patent/ES2171746T3/es not_active Expired - Lifetime
- 1996-11-13 JP JP51857397A patent/JP4264850B2/ja not_active Expired - Lifetime
- 1996-11-13 RU RU98111639/14A patent/RU2217144C2/ru not_active IP Right Cessation
- 1996-11-13 DK DK96939018T patent/DK0861081T3/da active
- 1996-11-13 AU AU76230/96A patent/AU706112B2/en not_active Ceased
- 1996-11-13 RO RO98-00922A patent/RO118373B1/ro unknown
- 1996-11-13 CA CA002232008A patent/CA2232008C/en not_active Expired - Fee Related
- 1996-11-13 EP EP96939018A patent/EP0861081B1/de not_active Expired - Lifetime
- 1996-11-13 PT PT96939018T patent/PT861081E/pt unknown
- 1996-11-13 PL PL96326653A patent/PL186615B1/pl not_active IP Right Cessation
- 1996-11-13 KR KR10-1998-0703549A patent/KR100435611B1/ko not_active IP Right Cessation
- 1996-11-13 TR TR1998/00853T patent/TR199800853T2/xx unknown
- 1996-11-13 AR ARP960105154A patent/AR004321A1/es unknown
- 1996-11-13 NZ NZ322467A patent/NZ322467A/xx not_active IP Right Cessation
- 1996-11-13 EE EE9800158A patent/EE03512B1/xx not_active IP Right Cessation
- 1996-11-13 WO PCT/EP1996/004957 patent/WO1997017971A1/de active IP Right Grant
- 1996-11-13 CN CN96198279A patent/CN1104242C/zh not_active Expired - Fee Related
- 1996-11-14 CO CO96060061A patent/CO4770978A1/es unknown
1998
- 1998-04-27 BG BG102408A patent/BG62511B1/bg unknown
- 1998-05-13 NO NO982172A patent/NO982172L/no not_active Application Discontinuation
1999
- 1999-02-11 HK HK99100562A patent/HK1015280A1/xx not_active IP Right Cessation
2008
- 2008-09-01 JP JP2008223046A patent/JP4850880B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EE9800158A (et)	1998-12-15
TR199800853T2 (xx)	1998-09-21
RU2238733C2 (ru)	2004-10-27
KR100435611B1 (ko)	2005-01-13
KR19990067527A (ko)	1999-08-25
SK61398A3 (en)	1998-09-09
AU706112B2 (en)	1999-06-10
MX9803206A (es)	1998-09-30
BG62511B1 (bg)	2000-01-31
HU225759B1 (en)	2007-08-28
EP0861081A1 (de)	1998-09-02
UY24354A1 (es)	2001-10-25
BG102408A (en)	1998-12-30
AR004321A1 (es)	1998-11-04
HK1015280A1 (en)	1999-10-15
BR9611502A (pt)	1999-03-02
PL326653A1 (en)	1998-10-12
ATE213160T1 (de)	2002-02-15
WO1997017971A1 (de)	1997-05-22
JP2000500446A (ja)	2000-01-18
DE19542281C2 (de)	1997-12-04
HUP9903489A3 (en)	2001-12-28
RU2217144C2 (ru)	2003-11-27
CN1202111A (zh)	1998-12-16
NO982172D0 (no)	1998-05-13
DE19542281A1 (de)	1997-05-15
DK0861081T3 (da)	2002-05-27
AU7623096A (en)	1997-06-05
CN1104242C (zh)	2003-04-02
IL123601A (en)	2002-12-01
IL123601A0 (en)	1998-10-30
DE59608738D1 (de)	2002-03-21
EP0861081B1 (de)	2002-02-13
JP4850880B2 (ja)	2012-01-11
RO118373B1 (ro)	2003-05-30
NO982172L (no)	1998-05-13
TW575423B (en)	2004-02-11
CZ149898A3 (cs)	1998-10-14
US5942503A (en)	1999-08-24
CA2232008C (en)	2004-01-06
JP2009019050A (ja)	2009-01-29
CZ290115B6 (cs)	2002-06-12
CO4770978A1 (es)	1999-04-30
ZA969520B (en)	1997-05-14
ES2171746T3 (es)	2002-09-16
EE03512B1 (et)	2001-10-15
HUP9903489A2 (hu)	2000-03-28
CA2232008A1 (en)	1997-05-22
NZ322467A (en)	2000-01-28
JP4264850B2 (ja)	2009-05-20
PT861081E (pt)	2002-06-28

Publication	Publication Date	Title
PL186615B1 (pl)	2004-02-27	Zastosowanie epinastyny
Grunberg et al.	1989	Dose ranging phase I study of the serotonin antagonist GR38032F for prevention of cisplatin-induced nausea and vomiting.
CA2112487C (en)	2003-04-15	Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
HU206042B (en)	1992-08-28	Process for producing pharmaceutical compositions comprising indole-3-carboxylic acid-endo-8-methyl-8-azabicyclo/3.2.1./oct-3-yl ester and/or 1,2,3-9-tetrahydro-9-methyl-3-(2-methyl-1h-imidazol-1-yl)-methyl-4h-carbazol-4-one, with an activity preventing or reducing opiate-, alcohol- and nicotine-dependence
JPH05507731A (ja)	1993-11-04	物質乱用障害の治療用医薬組成物
US5521178A (en)	1996-05-28	Combination medication containing flupirtin and morphine for the treatment of pain and the prevention of morphine dependence
CA2345406A1 (en)	2000-04-27	Analgesic
US5547956A (en)	1996-08-20	Pharmaceutical composition and the method for treating drug addicts' withdrawal syndromes and detoxifying addicts by the same
EP0694299A1 (en)	1996-01-31	The use of( a) bicycloheptane derivative(s)
AU2254692A (en)	1993-01-25	Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron
EP0900082A1 (en)	1999-03-10	Pyridyl- and pyrimidyl-piperazines in the treatment of substance abuse disorders
Kleber et al.	1987	The Physiology of Cocaine Craving and'Crashing'-Reply
US3743732A (en)	1973-07-03	Process for suppressing the tremor of parkinson's syndrome
MXPA98003206A (es)	1998-11-16	Empleo de epinastina para el tratamiento de dolores
WO1995019173A1 (en)	1995-07-20	Pharmaceutical compositions
Naylor et al.	1992	Mechanisms and Control of Emesis. Eds AL Bianchi, L. Grélot, AD Miller, GL King. Colloque INSERM/John Libbey Eurotext Ltd.© 1992, Vol. 223, pp. 115-127
US3743746A (en)	1973-07-03	Process of treating peptic ulcer with a non-anticholinergic agent
US3485921A (en)	1969-12-23	Analgesic and antitussive methods and compositions employing trans - (l)-3-(o-chlorophenyl) - 1,6-dimethyl-5-phenyl-1,4,5,6-tetrahydro-as-triazine
Wells et al.	1993	Serotonin and serotonergic drugs in emesis
JPS61191615A (ja)	1986-08-26	パーキンソン病またはパーキンソン症候群の治療用医薬組成物
Eadie et al.	1980	Disorders of Motor Function, II: Involuntary Movement Disorders

Legal Events

Date	Code	Title	Description
2013-12-31	LAPS	Decisions on the lapse of the protection rights	Effective date: 20121113